Prime Medicine (PRME) Cash & Equivalents: 2021-2025
Historic Cash & Equivalents for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $71.4 million.
- Prime Medicine's Cash & Equivalents fell 39.48% to $71.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year decrease of 39.48%. This contributed to the annual value of $182.5 million for FY2024, which is 338.92% up from last year.
- According to the latest figures from Q3 2025, Prime Medicine's Cash & Equivalents is $71.4 million, which was up 32.70% from $53.8 million recorded in Q2 2025.
- In the past 5 years, Prime Medicine's Cash & Equivalents registered a high of $200.7 million during Q3 2021, and its lowest value of $41.6 million during Q4 2023.
- For the 3-year period, Prime Medicine's Cash & Equivalents averaged around $91.5 million, with its median value being $91.9 million (2025).
- As far as peak fluctuations go, Prime Medicine's Cash & Equivalents plummeted by 77.84% in 2023, and later skyrocketed by 338.92% in 2024.
- Over the past 5 years, Prime Medicine's Cash & Equivalents (Quarterly) stood at $185.4 million in 2021, then rose by 1.19% to $187.6 million in 2022, then plummeted by 77.84% to $41.6 million in 2023, then skyrocketed by 338.92% to $182.5 million in 2024, then tumbled by 39.48% to $71.4 million in 2025.
- Its Cash & Equivalents stands at $71.4 million for Q3 2025, versus $53.8 million for Q2 2025 and $91.9 million for Q1 2025.